1. Search Result
Search Result
Results for "

phase transition

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

7

Biochemical Assay Reagents

3

Natural
Products

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1196

    NF-κB Inflammation/Immunology
    Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity. Suberosin suppresses PHA-induced PBMC proliferation and arrested cell cycle progression from the G1 transition to the S phase through the modulation of the transcription factors NF-AT and NF-κB .
    Suberosin
  • HY-104013
    Aminopurvalanol A
    1 Publications Verification

    CDK Apoptosis Cancer
    Aminopurvalanol A is a potent, selective, and cell permeable inhibitor of Cyclins/Cdk complexes. Aminopurvalanol A preferentially targets the G2/M-phase transition inhibiting cancer cell differentiation. Aminopurvalanol A causes the inhibition of sperm fertilizing ability via the inhibition of physiological capacitation-dependent actin polymerization .
    Aminopurvalanol A
  • HY-168210

    Fungal Cytochrome P450 Infection
    Antifungal agent 122 (compound 201) is a potent and broad-spectrum antifungal agent. Antifungal agent 122 prevents fungal phase transition and the formation of fungal biofilm. Antifungal agent 122 inhibits CYP3A4-M and CYP3A4-T enzyme activity with IC50 values of 2.11, 4.53 µM. Antifungal agent 122 shows no cytotoxicity .
    Antifungal agent 122
  • HY-W590535

    1,2-DNPC; 1,2-Dinonadecanoyl-sn-glycero-3-phosphocholine

    Liposome Cancer
    19:0 PC is a saturated phospholipid that has been used as a standard for the quantification of phosphatidylcholines in human synovial fluid. It has also been used to study dynamics of lipid bilayer phase transition.
    19:0 PC
  • HY-171458

    Fluorescent Dye Others
    U-104067 can be used as a molecular probe to observe and to quantitate a variety of physical phenomena, such as transfer into lipid membranes, partitioning between surface phases, and partitioning between lipid carriers and target membranes. U-104067 is a sensitive reporter of the tilt/ripple phase transition, monitored by its fluorescence anisotropy and quantum yield changes .
    U-104067
  • HY-155552

    Molecular Glues Apoptosis Cancer
    GSPT1 degrader-1 (compound 9q) is a potent degrader of G1 to S phase transition 1 (GSPT1) via ubiquitin-proteasome system, serves as one of Molecular Glues. GSPT1 degrader-1 also induces cell G0/G1 phase arrest and apoptosis .
    GSPT1 degrader-1
  • HY-W127423

    Biochemical Assay Reagents Others
    Methyl (+/-)-2-hydroxystearateis a hydroxylated fatty acid methyl ester that broadens phase transitions in dimyristoylphosphatidylcholine (DMPC) lipid membranes. It has been used in the synthesis of lipid-nucleotide conjugated anti-HIV agents to increase the cleavage of phosphodiester bonds and the number of released intracellular nucleotides.
    Methyl 2-hydroxyoctadecanoate
  • HY-146750

    HDAC Apoptosis Cancer
    HDAC-IN-37 is a potent HDAC inhibitor with IC50s of 0.0551 μM, 1.24 μM, 0.948 μM and 34.2 μM for HDAC1, HDAC3, HDAC8 and HDAC6, respectively. HDAC-IN-37 induces histone acetylation in a slow-off manner. HDAC-IN-37 prevents cell transition from G1 phase to S phase and induces early cell apoptosis .
    HDAC-IN-37
  • HY-156829C

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1)
  • HY-156829I

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution)
  • HY-156829J

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution)
  • HY-13650
    Indisulam
    Maximum Cited Publications
    12 Publications Verification

    E 7070

    Molecular Glues Carbonic Anhydrase Cancer
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .
    Indisulam
  • HY-156829B

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The higher the concentration, the lower the gelation temperature. The gelation temperature is between 31-34℃ at a concentration of 15-20 wt% .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1)
  • HY-156829E

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (15% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (15% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The higher the concentration, the lower the gelation temperature. The gelation temperature is between 31-34℃ at a concentration of 15-20 wt% .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (15% solution)
  • HY-156829H

    Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (20% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (20% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The higher the concentration, the lower the gelation temperature. The gelation temperature is between 31-34℃ at a concentration of 15-20 wt% .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) (20% solution)
  • HY-159610

    Molecular Glues Cancer
    PROTAC GSPT1 degrader-2 (compound A) is a GSPT1 molecule glue with more than 95% degradation. GSPT1 degrader-8 inhibits cell viability in HL-60 cells with an IC50 of 10 nM .
    PROTAC GSPT1 degrader-2
  • HY-159609

    PROTACs Cancer
    PROTAC GSPT1 degrader-1 (Compound F) is a PROTAC degrader for G1 to S phase transition protein 1 (GSPT1) that degrades GSPT1 with a rate of 95% (1 μM) GSPT1 and 86% (0.1 μM). PROTAC GSPT1 degrader-1 inhibits the cell viability of HL-60 with an IC50 of 9.2 nM. (Pink: ligand for target protein (HY-W599025); Black: linker (HY-159619); Blue: ligand for E3 ligase (HY-W087383))
    PROTAC GSPT1 degrader-1
  • HY-170405

    PROTACs mTOR Cancer
    YB-3-17 is a bifunctional molecule, that inhibits mTOR (IC50=0.22 nM) or degrades G1 to S phase transition 1 gene (GSPT1, DC50=5 nM) in a PROTAC mechanism. YB-3-17 exhibits antiproliferative activity in multi glioblastoma cell lines with IC50 of nanomolare levels. YB-3-17 exhibits antitumor efficacy in mouse models . (Pink: ligand for target protein (HY-170407); Black: linker (HY-A0102); Blue: ligand for E3 ligase Cereblon (HY-14658))
    YB-3–17
  • HY-N0837
    Veratramine
    1 Publications Verification

    NSC17821; NSC23880

    PI3K Akt mTOR Autophagy Apoptosis Neurological Disease Metabolic Disease Cancer
    Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .
    Veratramine
  • HY-153803

    PROTACs Molecular Glues Btk Cancer
    GBD-9 is a degrader based on the E3 ubiquitin ligase CRBN that targets BTK and the G1 to S phase transition protein GSPT1. GBD-9 has both PROTAC and molecular glue properties by inducing ubiquitination and proteasomal degradation of target proteins. GBD-9 can efficiently degrade wild-type and mutant BTK (such as C481S mutation) and GSPT1. GBD-9 significantly inhibits tumor cell proliferation by inducing G1 phase arrest in cancer cells, downregulating anti-apoptotic proteins (BCL-2, MCL-1) and activating Caspase-3 to induce apoptosis. GBD-9 is mainly used in the research of hematological tumors such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) .
    GBD-9 is composed of E3 ubiquitin ligase ligand (pink part) 5-Aminothalidomide (HY-W023573), target protein ligand (blue part) Btk Inhibitor: IBT6A (HY-13036A), and PROTAC linker (black part) Nonanoic acid (HY-N7057).
    GBD-9
  • HY-N0837R

    NSC17821 (Standard); NSC23880 (Standard)

    PI3K Akt mTOR Autophagy Apoptosis Neurological Disease Metabolic Disease Cancer
    Veratramine (NSC17821; NSC23880) (Standard) is the analytical standard of Veratramine (HY-N0837). This product is intended for research and analytical applications. Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .
    Veratramine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: